Form 8-K - Current report:
SEC Accession No. 0001193125-25-087390
Filing Date
2025-04-21
Accepted
2025-04-21 17:28:56
Documents
16
Period of Report
2025-04-15
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d198638d8k.htm   iXBRL 8-K 26589
2 EX-16.1 d198638dex161.htm EX-16.1 3578
6 GRAPHIC g198638g0422023946134.jpg GRAPHIC 2345
7 GRAPHIC g198638g0422023946393.jpg GRAPHIC 2446
  Complete submission text file 0001193125-25-087390.txt   168680

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apto-20250415.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apto-20250415_lab.xml EX-101.LAB 19468
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apto-20250415_pre.xml EX-101.PRE 12162
18 EXTRACTED XBRL INSTANCE DOCUMENT d198638d8k_htm.xml XML 3938
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 25854500
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)